SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Neuphoria Therapeutics Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% of Neuphoria Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', beneficially own 1,033,796 shares of Neuphoria Therapeutics Inc. Common Stock.
• This ownership represents 4.99% of the issuer's outstanding common stock.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment position.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares held by the Master Fund.
• Both reporting persons hold shared voting and shared dispositive power over all 1,033,796 shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

This Schedule 13G filing primarily concerns beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding Neuphoria Therapeutics Inc.'s future outlook.

Industry Context

This Schedule 13G filing primarily concerns beneficial ownership disclosure by an institutional investor and does not provide specific industry context or trends for Neuphoria Therapeutics Inc. or its competitors.

Key Dates

Keywords

Neuphoria Therapeutics Inc., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing